Welcome to this November twenty twenty-six run-through of Dermatologic Surgery. Four pieces on the docket this time — two original cross-sectional studies, a how-we-do-it technique piece, and a survey study — and they actually pair up nicely: pricing and access on one side, clinical decision-making and workflow on the other. Let's get into it. First up is a research communication titled "Commercial Pricing Variation for Dermatologic Surgery Services in the United States." This is a cross-sectional study, and it's tackling a problem that's more health-policy than histology, but one that increasingly bleeds into how we counsel patients about cost. Commercial payers account for the majority of dermatology payments in this country, yet until recently we've had almost no visibility into how commercial rates vary across payers, regions, and practice settings, or how they stack up against published Medicare rates. There was a prior study of hospital price transparency files suggesting real variation in Mohs pricing, but it was confined to a handful of academic centers. This group wanted the office-based picture, across the whole country. Methodologically, they leaned on the federal Transparency in Coverage rule, which as of mid twenty twenty-four forces insurers to publicly disclose their negotiated rates. They pulled rates from four major national payers — Aetna, Anthem, Cigna, and United Healthcare — for seven CPT codes spanning benign and malignant excision, Mohs surgery on the head and neck versus trunk and extremities, intermediate repair, complex repair, and adjacent tissue transfer. They linked every dermatologist's National Provider Identifier to a national physician file to classify practice setting, rurality, and region. This is really the only design available to answer this question at national scale — you can't survey your way to four hundred thousand negotiated price points, and the transparency files, whatever their flaws, are the first dataset that actually lets you do this comprehensively rather than anecdotally. For the statistics, they used the Kruskal-Wallis test to compare medians across subgroups — region, rurality, practice type. It's worth pausing on why. Kruskal-Wallis is the nonparametric cousin of one-way ANOVA: instead of comparing group means under an assumption of roughly normal, symmetric distributions, it ranks all the observations and asks whether the rank distributions differ across groups. That matters enormously here because price data are brutally skewed — look at those interquartile ranges, where a complex repair might run from four hundred-something dollars up past twelve hundred. With distributions that lopsided, a mean and a standard deviation would be misleading, and a Kruskal-Wallis test on ranks is the more honest tool when you're comparing more than two skewed groups at once. Onto results. They captured just under four hundred twenty-nine thousand negotiated rates from over twelve thousand five hundred dermatologists. Aggregate median rates across all services ranged from about five hundred fifty dollars for Aetna up to roughly six hundred seventy-five to six hundred eighty for Anthem, Cigna, and United. Regional variation was significant and not trivial — the highest-paying region beat the lowest by somewhere between seventeen and thirty-nine percent depending on payer, with the West and Midwest generally on top and the South and Northeast generally at the bottom. Counterintuitively, non-metro counties actually paid more than metro counties for three of the four payers, by about five to nineteen percent — probably reflecting network adequacy incentives in rural areas, though the authors don't say that explicitly. And practice consolidation mattered a lot: multispecialty groups and nonacademic hospitals negotiated rates eighteen to fifty-six percent higher than solo or small private practices, and academic centers did even better, thirty-two to ninety-six percent higher — all significant, with United Healthcare showing the widest spread. The Medicare comparison is the number I'd actually flag for practice relevance: commercial rates universally exceeded Medicare's nonfacility rate, with average markups ranging from about twelve percent for Aetna up to thirty-seven percent for Anthem. The gap was widest for complex repairs, about twenty-nine percent above Medicare, and tissue transfer, about twenty-two percent above. The authors frame this as consistent with similar commercial-pricing variation already documented in ophthalmology and general surgery, likely reflecting local market dynamics, cost-of-living differences, and simply different negotiating leverage. The consolidation finding is the more provocative thread — bigger groups and hospital-affiliated and academic practices commanding meaningfully higher negotiated rates supports the idea that market consolidation, including the ongoing private equity rollup of dermatology practices, is translating into negotiating power. They're appropriately cautious, though: this is associational, not causal, and they acknowledge they can't fully unpack why any given rate was negotiated, they only captured four insurers and seven codes, and facility-based rates weren't characterized at all, so this is office-based only. Where does this land for you practically? It's not practice-changing in the sense of altering how you treat a patient, but it's useful ammunition. If you're in a solo or small practice negotiating payer contracts, this gives you external benchmarks showing multispecialty and academic groups are getting substantially better rates for identical CPT codes — which is a legitimate talking point in negotiations. And for patient-facing cost conversations, particularly with high-deductible or coinsurance commercial plans, knowing that commercial rates for something like a complex repair or tissue transfer can run thirty percent or more above Medicare is genuinely useful when patients ask what something is going to cost them. Second article: "Evaluating Adherence to Recommended General Dermatology Follow-Up After Mohs Surgery." Another cross-sectional study, this time single-institution, out of Nebraska. The clinical premise is one we all operate under reflexively — patients with a keratinocyte carcinoma history are at substantially elevated risk for another one, so timely dermatologic follow-up after Mohs is standard of care. But nobody had actually looked at whether patients hit their recommended follow-up dates in real-world practice. They pulled this from a previously conducted retrospective cohort survey at an academic Mohs clinic, administered over about two and a half years, capturing demographics, skin cancer history, and immune status. They included patients who got general dermatology follow-up within the same health system and had an expected follow-up date that had already passed by at least three weeks before their cutoff date, so they could actually measure the gap. They compared actual versus recommended follow-up dates, stratified by sex, age, insurance, distance from the medical center, immune status, field cancerization classification, and baseline skin cancer count. Statistically, they used the Wilcoxon rank-sum test and Spearman correlation, which is a nice pairing to understand because they're solving two different problems with the same underlying logic. The Wilcoxon rank-sum, sometimes called Mann-Whitney, compares two groups by ranking all observations together and checking whether one group's ranks skew higher or lower — again, the nonparametric workhorse for data that aren't normally distributed, which delay times certainly aren't, since most patients are roughly on time and a subset trails off into many months of delay, creating a heavy right skew. Spearman correlation does something related but continuous — rather than comparing two discrete groups, it asks whether two continuous or ordinal variables move together, using ranks rather than raw values, so it captures monotonic relationships without assuming anything is linear and without being distorted by outliers. They used it here to check whether things like age or distance from clinic correlated with delay length. Results: two hundred nine participants, almost an even split of men and women, average age around sixty-nine, mostly immunocompetent. Overall, the median follow-up landed about one week after the recommended date, which was statistically significant but clinically a nonissue — a week of slack is nothing. The number that matters is this: more than one in three patients, about thirty-five percent, blew past the three-week adherence window entirely. And within that delayed group, the median delay wasn't a week, it was nearly sixteen weeks — close to four months beyond what was recommended. Critically, none of the stratifying variables — sex, age, insurance type, distance from the medical center, immune status, field cancerization class, or baseline skin cancer burden — predicted who fell into that delayed group. The authors' read, and it's a sensible one, is that because delay wasn't explained by any patient-level demographic or clinical factor, the driver is probably systemic — scheduling bottlenecks, communication breakdowns, competing life priorities — rather than anything about the patient themselves. They tie the stakes back to the literature: patients with a keratinocyte carcinoma history are at least ten times more likely to develop another within three years, and separately, a roughly four-month delay in diagnosing a keratinocyte carcinoma has been shown to meaningfully increase tumor surface area and thickness, which complicates repair and raises recurrence and metastasis risk. The limitations aren't heavily spelled out by the authors beyond the obvious — single academic center, a sample built from patients who had already agreed to participate in a separate survey study, so there's some selection built in, and EMR-derived follow-up dates that can't tell you why a given patient was late. The practical takeaway here actually is close to practice-changing, at least operationally. Since delay doesn't track with who the patient is, the fix has to be structural rather than patient-targeted — don't bother risk-stratifying who needs extra reminders, build the safety net for everyone. The concrete suggestions the authors offer, several of which they say are already in use in their own clinics, are worth adopting wholesale if you aren't already: book the general dermatology follow-up on the day of Mohs surgery or at the wound check rather than leaving it to the patient to call later, use real-time online self-scheduling so patients aren't stuck waiting on hold, and layer in automated text reminders. None of that requires new evidence to justify — it's cheap, low-risk, and directly targets a documented one-in-three failure rate in your own likely patient population. Third, a How We Do It piece: "Bone Wax Dressing in Dermatologic Surgery." This is a technique article, so no methods-and-results scaffolding here — just the clinical problem, the maneuver, and the rationale. The setting is staged facial reconstruction, particularly slow Mohs, where excision and definitive closure can't happen in the same sitting — think permanent-section margin confirmation rather than frozen section, or an elderly, comorbid patient where you deliberately want to minimize operative time and let secondary intention bridge the gap. The authors describe three consecutive slow Mohs cases where the fresh defect was packed with bone wax, covered with sterile gauze, and secured with adhesive fabric tape. That gave immediate compressive hemostasis while preserving the exact defect geometry and margin integrity — no granulation tissue creeping in to obscure the surgical field. Dressings were changed weekly with fresh wax at each visit, and once clear margins were confirmed histologically at around the two-week mark, the wax lifted off cleanly with no granulation tissue and no local tissue injury. The eventual reconstructions in these three cases were a glabellar rotation flap, an east-west flap, and a nasalis sling flap — so bone wax was purely the bridge, not the final answer. They also describe a second use case: an interpolated paranasal flap, where bone wax was tucked beneath the pedicle itself. There it controlled bleeding and exudate, physically protected the pedicle, and meaningfully cut down on how often dressings needed changing. It stayed in place two weeks with weekly exchanges and came off without incident at pedicle division. The rationale they give is mechanical tamponade — bone wax achieves hemostasis by physically occluding the surgical field, a principle borrowed from neurosurgery and now extended into trauma and cutaneous surgery. Modern formulations are beeswax plus isopropyl palmitate and stabilizers, cheap relative to advanced wound dressings, biologically inert, nonallergenic, nonadherent, moldable with gentle warming to fit complex contours, and easy to remove without tissue trauma. It also creates a moist, occlusive microenvironment that favors granulation when you do want it to heal by secondary intention. The one caveat they raise is that because it's not absorbable, prolonged retention can provoke foreign-body granulomas — a real issue in neurosurgery and orthopedics where it's sometimes left in place indefinitely — but they note that's simply not a relevant concern given the short dermatologic dwell times described here. They also cite a comparative study of scalp defects healed by secondary intention showing bone wax performed comparably to a dermal regeneration matrix on epithelialization time, complications, and cosmetic outcome, while being simpler to use and considerably cheaper. There's no results-and-limitations arc to walk through since this is a pearls piece, but the practical takeaway is straightforward: if you're doing slow Mohs or any staged facial reconstruction where you need a temporary, hemostatic, shape-preserving interim dressing — especially around the eyes, nose, or pedicled flaps — bone wax is a genuinely low-cost, low-fuss option worth having in your armamentarium, and this adds incrementally to a small but consistent body of supporting experience. Last one: "Surgical Management of Dysplastic Nevi: A Survey Study." This is exactly what it says — a descriptive survey, not a comparative trial, so there's no inferential statistics to teach here, just percentages describing practice patterns. The background will be familiar frustration to anyone who excises pigmented lesions: dysplastic nevi remain a conceptually messy category. It's not settled whether they're true malignant precursors, just undersampled melanocytic lesions, or simply markers of elevated melanoma risk, and dermatopathologists show poor agreement on grading, on whether to even comment on margin status, and on whether to recommend excision at all. The 2015 Pigmented Lesions Subcommittee guidelines tried to bring order: completely sampled mild dysplastic nevi can be observed regardless of margin status, moderate dysplastic nevi with negative margins can be observed, and severe dysplastic nevi with positive margins should be excised. But two scenarios were explicitly left unresolved — moderate dysplastic nevi with positive margins, and severe dysplastic nevi with negative margins. This survey set out to see what surgeons are actually doing in those gray zones. They built an anonymous Google Forms survey, distributed through the American College of Mohs Surgery and the Association of Professors of Dermatology listservs, open for six weeks, restricted to board-certified dermatologists who'd excised at least one dysplastic nevus in the prior year. A hundred eleven people accessed it, and a hundred three, or about ninety-three percent, qualified. The respondent pool skewed toward urban or suburban practice, split roughly evenly between academic and private practice, with about seventy-two percent having completed a Mohs and dermatologic oncology fellowship and just over half spending more than three-quarters of their clinical time on surgery — so this is a reasonably surgically-concentrated sample, which matters for interpreting the findings. On pathology reporting practices: ninety-four percent of respondents' labs grade dysplastic nevi as mild, moderate, or severe; only about two-thirds of pathologists comment on margin involvement at all, and only sixty percent comment on whether excision is recommended — underscoring just how much variability starts upstream, before the surgeon even makes a decision. For mild dysplastic nevi, there was essentially universal consensus: nobody routinely excises them, though a small minority, under nine percent, said they'd consider it under specific circumstances like positive margins or visible residual pigment. Moderate dysplastic nevi is where things fall apart — about fifteen percent always excise, thirty-one percent never excise, thirty-six percent excise specifically when margins are positive, and the remaining quarter make a case-by-case call based on things like patient factors, lesion location, clinical residual pigment, or a pathologist's suggestion. When they do excise moderate lesions, the dominant margin was two to three millimeters, used by about three-quarters of respondents. Severe dysplastic nevi swung back to near-consensus in the other direction — ninety-six percent always excise regardless of margin status, and the majority, fifty-seven percent, use a margin of five millimeters or more, essentially treating it like melanoma in situ. And for the ambiguous "atypical intraepidermal melanocytic proliferation" read — essentially a punt from pathology that avoids committing to melanoma in situ language — three-quarters of respondents still excised with three-to-five millimeter margins. Opinion was split almost down the middle, forty-two versus fifty-seven percent, on whether anatomic location should influence management at all. The authors' interpretation lines up with what the numbers show: moderate dysplastic nevi with positive margins is genuinely the most contested territory, consistent with the guideline gap, and surgeons are filling that gap with a mix of margin status, patient and lesion factors, and deference to pathologist judgment — with more than a third of the cohort specifically weighting margin positivity. For severe dysplastic nevi with negative margins, the near-universal practice of excising anyway, despite the guidelines technically not requiring it, likely reflects real distrust in interobserver consistency among pathologists and a reasonable fear of an under-read melanoma hiding underneath that label. They're appropriately candid about limitations — an unknown response rate, a modest absolute number of respondents, and the inherent recall and response bias of any self-reported survey. Is this practice-changing? Not really — it doesn't resolve anything or hand you new evidence to act on. But it is a legitimate benchmarking tool: if your own approach to moderate dysplastic nevi with positive margins, or severe dysplastic nevi with negative margins, differs sharply from this cohort, it's worth knowing you're an outlier, even if there's no proof yet that any one approach is superior. The honest message from the authors is that both of those unresolved scenarios need actual outcomes data — particularly whether severe dysplastic nevi with negative margins could safely be observed rather than reflexively excised — before anyone can turn survey consensus into guideline consensus. That wraps this issue. To summarize the through-line: commercial pricing for office-based dermatologic surgery varies substantially by region, rurality, and practice consolidation, and consistently runs above Medicare, which is useful context for contracting and cost conversations but doesn't change clinical care; post-Mohs follow-up adherence has a real and underappreciated failure rate that looks systemic rather than patient-driven, which is an actionable workflow fix for any Mohs practice; bone wax remains a cheap, well-tolerated bridge dressing worth keeping in mind for staged reconstructions; and dysplastic nevus management continues to live in real clinical gray zones, with this survey mapping current practice patterns rather than resolving them. Thanks for listening, and I'll see you next issue.